Roche Introduces in-situ Hybridisation Test To Help Pathologists

Roche, a swiss based healthcare firm, declared the launch of the first clinically approved, highly sensitivity in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay in nations embracing the CE Mark...

Aethlon Medical Receives HREC's Nod for Hemopurifier Cancer Trial

Aethlon Medical, Inc., a medical therapeutic company dedicated to creating products to treat cancer and life-threatening infectious illnesses, declared that the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network...

US FDA Nod Merck's Keytruda Plus Carboplatin And Paclitaxel

Merck reported that the US Food and Drug Administration (FDA) has approved Keytruda, the company's anti-PD-1 medication, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients...

LSL Pharma Group Concludes the Acquisition of Virage Sante

LSL PHARMA GROUP INC., a Canadian based pharmaceutical firm, is pleased to declare the acquisition of Virage Santé, a firm, that specializes in the production and distribution of natural health products (NHPs). LSL Pharma's contract development...

Cipla To Fund Additional 3 Million Euros in Ethris

Cipla, a leading global pharmaceutical firm, announced that it will make an additional investment of 3 million euros in Ethris, a company based in Germany that is developing potential treatments for respiratory diseases using its own mRNA...

Aprea Therapeutics Commences Patient Dosing in Phase 1 Trial

Aprea Therapeutics, Inc., a biopharmaceutical firm that specializes in precision oncology through synthetic lethality, declared that the first patient has been dosed in the ACESOT-1051 phase 1 study. The study evaluates which is evaluating the...

© 2024 India Pharma Outlook. All Rights Reserved.